-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SHRA-1904 in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SHRA-1904 in Pancreatic Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SHRA-1904 in Pancreatic Cancer Drug Details: SHRA-1904 is under development for...
-
Product Insights
Myocarditis – Drugs In Development, 2023
Global Markets Direct’s, ‘Myocarditis - Drugs In Development, 2023’, provides an overview of the Myocarditis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Myocarditis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Myocardial Fibrosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Myocardial Fibrosis - Drugs In Development, 2023’, provides an overview of the Myocardial Fibrosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Myocardial Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Diastolic Heart Failure – Drugs In Development, 2023
Global Markets Direct’s, ‘Diastolic Heart Failure - Drugs In Development, 2023’, provides an overview of the Diastolic Heart Failure pipeline landscape. The report provides comprehensive information on the therapeutics under development for Diastolic Heart Failure, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AU-314 in Breast Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. AU-314 in Breast Cancer Drug Details: AU-314 is under development for the treatment of solid...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cannabidiol 1 in Pericarditis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Cannabidiol 1 in Pericarditis Drug Details: Cannabidiol is under development for the treatment of diastolic heart...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cannabidiol 1 in Myocarditis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cannabidiol 1 in Myocarditis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Cannabidiol 1 in MyocarditisDrug Details:Cannabidiol is under development for the treatment of diastolic heart...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – cannabidiol 1
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry cannabidiol 1 Drug Details Cannabidiol is under development for the treatment of steroid-dependent Crohn's...
-
Product Insights
Myocarditis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Myocarditis pipeline market research report provides comprehensive information on the therapeutics under development for Myocarditis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Myocarditis and features dormant and discontinued projects.
-
Product Insights
Congestive Heart Failure (Heart Failure) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Congestive heart failure (heart failure) report provides comprehensive information on the therapeutics under development for Congestive Heart Failure (Heart Failure), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Congestive Heart Failure...